1. Home
  2. ADMA vs ABVX Comparison

ADMA vs ABVX Comparison

Compare ADMA & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADMA
  • ABVX
  • Stock Information
  • Founded
  • ADMA 2004
  • ABVX 2013
  • Country
  • ADMA United States
  • ABVX France
  • Employees
  • ADMA N/A
  • ABVX N/A
  • Industry
  • ADMA Biotechnology: Biological Products (No Diagnostic Substances)
  • ABVX
  • Sector
  • ADMA Health Care
  • ABVX
  • Exchange
  • ADMA Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • ADMA 5.1B
  • ABVX 5.3B
  • IPO Year
  • ADMA N/A
  • ABVX N/A
  • Fundamental
  • Price
  • ADMA $17.80
  • ABVX $77.28
  • Analyst Decision
  • ADMA Strong Buy
  • ABVX Buy
  • Analyst Count
  • ADMA 3
  • ABVX 7
  • Target Price
  • ADMA $27.67
  • ABVX $74.86
  • AVG Volume (30 Days)
  • ADMA 3.3M
  • ABVX 1.2M
  • Earning Date
  • ADMA 08-06-2025
  • ABVX 08-11-2025
  • Dividend Yield
  • ADMA N/A
  • ABVX N/A
  • EPS Growth
  • ADMA 469.09
  • ABVX N/A
  • EPS
  • ADMA 0.85
  • ABVX N/A
  • Revenue
  • ADMA $474,174,000.00
  • ABVX $11,444,012.00
  • Revenue This Year
  • ADMA $21.11
  • ABVX N/A
  • Revenue Next Year
  • ADMA $25.97
  • ABVX $41.36
  • P/E Ratio
  • ADMA $20.93
  • ABVX N/A
  • Revenue Growth
  • ADMA 43.58
  • ABVX 128.98
  • 52 Week Low
  • ADMA $13.50
  • ABVX $4.77
  • 52 Week High
  • ADMA $25.67
  • ABVX $78.26
  • Technical
  • Relative Strength Index (RSI)
  • ADMA 51.09
  • ABVX 82.10
  • Support Level
  • ADMA $16.93
  • ABVX $67.15
  • Resistance Level
  • ADMA $17.90
  • ABVX $71.45
  • Average True Range (ATR)
  • ADMA 0.86
  • ABVX 3.26
  • MACD
  • ADMA 0.04
  • ABVX -1.63
  • Stochastic Oscillator
  • ADMA 59.11
  • ABVX 89.39

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: